In 2025, women’s health faced a mix of progress and challenges. Innovations like the first new copper IUD in decades and a new class of antibiotics for UTIs emerged, but the rise in maternal mortality due to cardiovascular disease raised alarms.
This year brought significant stories in women’s health. One highlight was the FDA’s approval of Miudella, a non-hormonal copper IUD, the first of its kind in over 40 years. Dr. David K. Turok, who led clinical trials on Miudella, expressed excitement about its potential to improve women’s choices, especially for those looking for alternatives to hormonal contraception. The device showed high efficacy, with a remarkable Pearl Index of about 1.0, keeping the pregnancy rate low over three years.
Meanwhile, maternal mortality rates from cardiovascular issues have alarmingly doubled since 1999, rising from 3.6 to 9.1 per million women. The disparity is striking, with Black women facing a mortality rate nearly three times that of their White counterparts. Dr. Mohammad Ahabab Hossain pointed to rising heart disease and related health conditions, like hypertension and diabetes, as significant contributors. He noted that many complications are preventable with proper prenatal care and attention for at-risk patients.
In a significant move against rising antibiotic resistance, the FDA approved gepotidacin (Blujepa) for treating uncomplicated UTIs. After nearly 30 years without a new class of oral antibiotics, this approval was celebrated for its unique approach to target bacterial DNA replication, making it a promising option for women dealing with recurrent infections.
Before the government shutdown in October, the FDA quietly approved a generic version of mifepristone, a key medication for abortion. This was a pivotal moment but one wrapped in controversy due to varying state laws following the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization. Pharmacists like Nicole Cieri-Hutcherson are increasingly crucial in guiding patients through these changes in access and care.
Lastly, expanding over-the-counter (OTC) contraceptives has gained support. Research published in Contraception reveals that Black and Hispanic populations are more likely to choose OTC options, which can help bridge existing healthcare gaps. This approach can especially benefit those who face barriers due to past negative healthcare experiences.
As women’s health continues to evolve, we must remain aware of both innovations and ongoing disparities. Staying informed helps us advocate for the improvements needed in healthcare access and choices.
